drugset / Trial / NCT05549206
A Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in Chinese People
Unknown
350 enrolled
AIM Vaccine Co., Ltd.
Ningbo Rongan Biological Pharmaceutical Co., Ltd. · collabThe First Affiliated Hospital of Bengbu Medical University · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
This is a cohort study to evaluate safety and immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in participants aged 18 years and over in China
Timeline
- Start
- 2023-04
- Primary completion
- 2023-04
- Completion
- 2024-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LVRNA012 | Messenger RNA (mRNA) | 50 ug | Intramuscular |
| Subject | LVRNA012 | Messenger RNA (mRNA) | 100 ug | Intramuscular |